HC
NRSN icon

Hurley Capital’s NeuroSense Therapeutics NRSN Stock Holding History

Hurley Capital’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-327
Closed -$12.3K – 696
2025
Q2 		$12.3K Sell
327
-109
-25% -$3.16K 0.01% 288
2025
Q1 		$8.1K Buy
+436
New +$9.64K 0.01% 343

Other funds holding NRSN

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Hurley Capital's NRSN Position: Q3 2025 in Review

Hurley Capital sold out of NeuroSense Therapeutics (NRSN) in Q3 2025, closing a stake of 327 shares — an estimated $12.3K sold.

Hurley Capital first reported a position in NRSN in Q1 2025 and held it in 2 quarters. The position peaked at $12.3K in Q2 2025. 10 funds tracked by Wall St. Rank hold NRSN as of Q3 2025.

  • Hurley Capital reported no remaining NeuroSense Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Hurley Capital sold 327 NeuroSense Therapeutics shares in Q3 2025, an estimated $12.3K.
  • Hurley Capital first reported a position in NeuroSense Therapeutics in Q1 2025 and held it in 2 quarters.
  • Hurley Capital's NeuroSense Therapeutics position peaked at $12.3K in Q2 2025.
  • 10 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2025.

Based on Hurley Capital's 13F filing for Q3 2025, filed 12 Nov 2025.